|
Jun 11
|
Co-Founder of Context Therapeutics Martin Lehr Buys 10% More Shares
|
|
May 7
|
Context Therapeutics Reports First Quarter 2025 Operating and Financial Results
|
|
May 5
|
Context Therapeutics Announces Chief Medical Officer Transition
|
|
Jan 15
|
Context doses first subject in Phase I cancer trial of CTIM-76
|
|
Jan 14
|
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
|
|
Aug 27
|
Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year?
|
|
Aug 7
|
Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results
|
|
Aug 6
|
Context Therapeutics Inc.'s (NASDAQ:CNTX) top owners are individual investors with 52% stake, while 30% is held by private equity firms
|
|
Jun 12
|
Is CareCloud (CCLD) Stock Outpacing Its Medical Peers This Year?
|
|
May 20
|
Are You Looking for a Top Momentum Pick? Why Context Therapeutics Inc. (CNTX) is a Great Choice
|
|
Nov 9
|
Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results
|
|
Aug 10
|
Context Therapeutics CEO Marty Lehr notes progress towards the clinic with CTIM-76 in 2Q update
|
|
Aug 9
|
Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results
|
|
Apr 24
|
Context Therapeutics CTIM-76 bispecific antibody preclinical data presented at AACR Annual Meeting
|